A leading consortium of industrial partners has been awarded a grant by the Seventh Framework Program of the European Union for an innovative research and development project “TA101 GOCLIN: Clinical development of TA-101 for the treatment of rheumatoid arthritis” (#606352). The aim of this Project is to take TA101, a small domain antibody developed by TechnoPhage, into the clinical stage of development for rheumatoid arthritis (RA) and develop a novel mode of administration for the market of biologic therapeutics. The project is forecasted for completion in 2015, with a total duration of 26 months. The total budget is EUR 1,72 million corresponding to a total European funding of EUR 1,36 million.
TechnoPhage: TA101 GOCLIN European funded project for the development of an innovative product for the treatment of rheumatoid arthritis
31 Dez 2013 | News